International Business Machines Corp vs Twist Bioscience Corp — how do they compare? International Business Machines Corp trades at $235.59 (market cap $224.62B), while Twist Bioscience Corp trades at $122.96 (market cap $7.72B). The key difference: International Business Machines Corp is far larger — about 29.1× Twist Bioscience Corp's market cap, and International Business Machines Corp pays a 2.84% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| IBM | TWST | |
|---|---|---|
Market Cap | $224.62B | $7.72B |
Volume | 4,481,527 | — |
Sector | Technology | Health |
52-Week High | $329.23 | $124.88 |
52-Week Low | $205.77 | $24.16 |
Enterprise Value | $281.76B | $7.65B |
Dividend Yield | 2.84% | — |
Signals from Pluang's Aura AI — not financial advice
IBM trades at $234.91, down 0.59% today, with a mixed technical outlook showing bearish moving averages but bullish overall signals. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results pending. The company secured a $240 million AI deal with Together AI, boosting sentiment, but faces a securities fraud investigation following a 25% stock drop. Fundamentals are solid with revenue growth to $67.54 billion in 2025 and a net income margin of 15.52%, though cash flow turned negative.
Outlook is cautiously optimistic with a consensus price target of $257.38, implying 9.6% upside, supported by AI and cloud growth. Risks include the ongoing fraud probe, competitive pressures, and high debt levels. Investors should weigh strong profitability against legal and execution uncertainties in a volatile market.
Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.
Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.
Trailing returns across standard periods
Latest headlines on both assets
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →